Ardent Health initiated with a Buy at BofA

BofA initiated coverage of Ardent Health with a Buy rating and $22 price target. Ardent Health is well-positioned to to surpass the industry’s 6% growth compound annual growth rate over the next decade given its position in markets with strong population growth, which should help drive margin expansion with upside optionality from capital deployment, the analyst tells investors in a research note.